Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nanocrystal megestrol acetate is an advanced oral formulation of **megestrol acetate** engineered using nanocrystal technology to enhance its bioavailability, especially under fasting conditions. Traditional micronized megestrol acetate oral suspensions, such as Megace OS, have limited absorption when taken without food. The nanocrystal formulation overcomes this by allowing for rapid and efficient absorption, leading to significantly higher systemic drug exposure even in the fasting state. Megestrol acetate is a synthetic progestin used primarily to stimulate appetite and promote weight gain in patients with cancer-associated anorexia, cachexia, or wasting syndromes. It also possesses antineoplastic effects and has been used in therapy for certain cancers such as breast and endometrial cancer. The predominant mechanism of action is as an agonist at the progesterone receptor. The nanocrystal formulation does not alter the pharmacodynamics of megestrol acetate but significantly optimizes its pharmacokinetic profile[1][2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nanocrystal megestrol acetate.